Physician profile
Ajit Nanda
NPI 1942286620
$756.08
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.82 · 2020: $213 · 2021: $390 · 2022: $87.28 · 2023: $45.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $197.17 | 2020-2022 | |
| Glaxosmithkline, LLC. | $84.99 | 2020-2023 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $82.77 | 2021 | |
| Esperion Therapeutics, INC. | $67.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $57.28 | 2020-2021 | |
| Lilly USA, LLC | $39.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.07 | 2020 | |
| Amgen INC. | $32.35 | 2021-2023 | Otezla, Repatha |
| Novo Nordisk INC | $28.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.76 | 2022 | |
| Corcept Therapeutics | $19.82 | 2019 | |
| Seqirus USA INC | $17.24 | 2021 | |
| Boston Scientific Corporation | $15.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.02 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.